Out-licensing innovative pipelines in ophthalmology and CNS
Tsubota Laboratory, Inc. is a privately held clinical development stage company focusing on out-licensing the pipelines in ophthalmology and CNS which are the novel patented research works of Keio University School of Medicine in Japan.
Our lead technology, violet light emitting eyeglass frame, is a versatile medical device (class II) technology. The target indication of this violet technology in ophthalmology includes, but is not limited to, prevention of myopia and treatment of keratoconus whereas that for CNS includes treatment of Parkinson’s disease, depression and mild cognitive impairment (MCI). For prevention of myopia, we have completed exploratory clinical trial (phase I/II) in FY2020 in Japan and demonstrated the safety and efficacy of device and now proceeding to pivotal study (phase III) starting FY2022 in Japan..
Another pipleline 4-PBA, a small molecule compound, is a novel approach to prevent myopia development by alleviating collagen remodeling of a sclera. Axial length elongation, increased in refractive error or expression of UPR-related genes were significantly inhibited for 4-PBA treated group compared to control.